Vincerx Pharma, Inc.
VINC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VINC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VINC
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecule-drug conjugates (SMDCs), but faces significant financial challenges and has not yet generated revenue.
Key risk: Cash runway and liquidity
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2025.
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecule-drug conjugates (SMDCs), but faces significant financial challenges and has not yet generated revenue.
- Vincerx is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies, including next-generation ADC compounds (VIP943, VIP924) and an SMDC (VIP236) [sec_mda · as of 2024-11-12].
- As of March 31, 2025, the company reported cash and equivalents of $4.5M, net income of -$5.0M, and shareholders' equity of $2.7M [sec].
- The company has not generated any revenue from product sales and does not expect to in the foreseeable future [sec_mda · as of 2024-05-14].
- A capital-raising effort in early 2024 was unsuccessful after investors deemed data insufficient, though a subsequent offering raised ~$16.5M, below the amount needed to support continued development of VIP236 and VIP943 [sec · filed 2025-05-12].
- VIP236 showed a 45% disease control rate in a Phase 1 trial with 20 evaluable patients, with no dose-limiting side effects commonly associated with camptothecins [sec · filed 2024-10-07].
What works
- VIP236 demonstrated a favorable safety profile with no instances of life-threatening diarrhea, severe stomatitis/mucositis, or interstitial lung disease in 29 patients [sec · filed 2024-10-07].
- The company's bioconjugation platform includes next-generation ADC compounds targeting known and novel oncology targets, potentially offering improved safety and efficacy [sec_mda · as of 2024-11-12].
- VIP236 showed promising monotherapy duration of response, with one patient on treatment for over 300 days and four additional patients on study for more than 120 days [sec · filed 2024-10-07].
What to weigh
- As of March 31, 2025, the company had only $4.5M in cash and equivalents, with a net loss of $5.0M for the quarter, indicating a limited cash runway [sec].
- The company has not generated any revenue and does not expect to in the foreseeable future, relying on external financing to fund operations [sec_mda · as of 2024-05-14].
- A capital-raising effort in early 2024 failed after investors deemed data insufficient, and a subsequent offering raised only ~$16.5M, below the capital required to support continued development of VIP236 and VIP943 [sec · filed 2025-05-12].
- Net working capital decreased from $9.1M to $1.1M between fiscal year 2023 and 2024, primarily due to cash used in operations [sec_mda · as of 2025-03-27].
From the filings
Quoted directly from source documents.
VIP236 showed a 45% disease control rate in a Phase 1 trial.
“nine of 20 patients had stable disease for a disease control rate of 45%”
SEC filings · October 7, 2024
The company has not generated any revenue and does not expect to in the foreseeable future.
“To date, we have not generated any revenue from any source, including the commercial sale of approved drug products, and we do not expect to generate revenue in the foreseeable futur”
SEC MD&A · May 14, 2024
A capital-raising effort was unsuccessful after investors deemed data insufficient.
“Investors did not view the data as sufficient to support the proposed financing, and the capital-raising effort was unsuccessful.”
SEC filings · May 12, 2025
VIP236 had no dose-limiting side effects commonly associated with camptothecins.
“no instances of the dose-limiting side effects commonly associated with camptothecins, such as life-threatening diarrhea, severe stomatitis/mucositis, or interstitial lung disease”
SEC filings · October 7, 2024
Risks & what to watch (4)›
Key risks
- Cash runway and liquidity — Only $4.5M cash as of March 31, 2025, with ongoing operating losses; may need additional funding soon [sec].
- No revenue generation — Company has no approved products and no revenue, relying entirely on external financing [sec_mda · as of 2024-05-14].
- Clinical development risk — VIP236 and VIP943 are in early stages; data may not support further development or financing [sec · filed 2025-05-12].
- Dependence on partnerships — Company intensified efforts to secure a strategic partnership after failed capital raise, but no guarantee of success [sec · filed 2025-05-12].
What to watch
- Ability to secure additional financing or a strategic partnership to fund continued development of VIP236 and VIP943 [sec · filed 2025-05-12].
- Clinical data updates from ongoing trials of VIP236 and other pipeline candidates [sec · filed 2024-10-07].
- Cash burn rate and any changes in liquidity position, given the low cash balance as of March 31, 2025 [sec].
- Progress in preclinical and clinical development of next-generation ADC compounds VIP943 and VIP924 [sec_mda · as of 2024-11-12].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Vincerx Pharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vincerx Pharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.1 months
D/E 1.27
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
as of May 22, 2026- % of float
- 2.7%
- Days to cover
- 0.1
- Shares short
- 137,204
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VINC short interestFrequently asked questions
What is the AI investment thesis for Vincerx Pharma, Inc.?
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecule-drug conjugates (SMDCs), but faces significant financial challenges and has not yet generated revenue.
Who is the CEO of Vincerx Pharma, Inc.?
Dr. Raquel E. Izumi Ph.D. is the chief executive officer of Vincerx Pharma, Inc. (VINC).
Where is Vincerx Pharma, Inc. headquartered?
Vincerx Pharma, Inc. (VINC) is headquartered in San Mateo, CA, United States.
What therapeutic areas does Vincerx Pharma, Inc. focus on?
Vincerx Pharma, Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.